BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gottlieb SL, Ndowa F, Hook EW 3rd, Deal C, Bachmann L, Abu-Raddad L, Chen XS, Jerse A, Low N, MacLennan CA, Petousis-Harris H, Seib KL, Unemo M, Vincent L, Giersing BK; Gonococcal Vaccine PPC Expert Advisory Group. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020;38:4362-73. [PMID: 32359875 DOI: 10.1016/j.vaccine.2020.02.073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Bagwe P, Bajaj L, Gala RP, D‘souza MJ, Zughaier SM. Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated Neisseria gonorrhoeae Microparticle Vaccine Formulation. Vaccines 2022;10:983. [DOI: 10.3390/vaccines10070983] [Reference Citation Analysis]
2 Maurakis SA, Cornelissen CN. Recent Progress Towards a Gonococcal Vaccine. Front Cell Infect Microbiol 2022;12:881392. [DOI: 10.3389/fcimb.2022.881392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Whittles LK, Didelot X, White PJ. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(21)00744-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang B, Giles L, Andraweera P, Mcmillan M, Almond S, Beazley R, Mitchell J, Lally N, Ahoure M, Denehy E, Koehler A, Flood L, Marshall H. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(21)00754-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Williams E, Fairley CK, Williamson D. Novel strategies for prevention and treatment of antimicrobial resistance in sexually-transmitted infections. Curr Opin Infect Dis 2021;34:591-8. [PMID: 34545855 DOI: 10.1097/QCO.0000000000000793] [Reference Citation Analysis]
6 Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, Ndowa F, Martin I, Dillon JR, Galas M, Ramon-pardo P, Weinstock H, Wi T. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. The Lancet Microbe 2021;2:e627-36. [DOI: 10.1016/s2666-5247(21)00171-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
7 Semchenko EA, Seib KL. Outer membrane vesicle vaccines for Neisseria gonorrhoeae. Nat Rev Urol 2021. [PMID: 34716431 DOI: 10.1038/s41585-021-00534-5] [Reference Citation Analysis]
8 Stewart J, Baeten JM. HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. Nat Rev Urol 2021. [PMID: 34697493 DOI: 10.1038/s41585-021-00527-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Harvey SM, Gibbs SE, Sikora AE. A Critical Need for Research on Gonorrhea Vaccine Acceptability. Sex Transm Dis 2021;48:e116-8. [PMID: 33201020 DOI: 10.1097/OLQ.0000000000001331] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Haese EC, Thai VC, Kahler CM. Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea. Vaccines (Basel) 2021;9:804. [PMID: 34358218 DOI: 10.3390/vaccines9070804] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Mitchev N, Singh R, Allam M, Kwenda S, Ismail A, Garrett N, Ramsuran V, Niehaus AJ, Mlisana KP. Antimicrobial resistance mechanisms, MLST and NG-STAR sequence types of diverse Neisseria gonorrhoeae isolates in KwaZulu-Natal, South Africa. Antimicrob Agents Chemother 2021;:AAC0075921. [PMID: 34280016 DOI: 10.1128/AAC.00759-21] [Reference Citation Analysis]
12 Whelan J, Eeuwijk J, Bunge E, Beck E. Systematic Literature Review and Quantitative Analysis of Health Problems Associated with Sexually Transmitted Neisseria gonorrhoeae Infection. Infect Dis Ther 2021. [PMID: 34279817 DOI: 10.1007/s40121-021-00481-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Unemo M, Ahlstrand J, Sánchez-Busó L, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ; European Collaborative Group. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018. J Antimicrob Chemother 2021;76:1221-8. [PMID: 33564854 DOI: 10.1093/jac/dkab024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
14 Sánchez-Busó L, Yeats CA, Taylor B, Goater RJ, Underwood A, Abudahab K, Argimón S, Ma KC, Mortimer TD, Golparian D, Cole MJ, Grad YH, Martin I, Raphael BH, Shafer WM, Town K, Wi T, Harris SR, Unemo M, Aanensen DM. A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at Pathogenwatch. Genome Med 2021;13:61. [PMID: 33875000 DOI: 10.1186/s13073-021-00858-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
15 Baarda BI, Zielke RA, Holm AK, Sikora AE. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates. mSphere 2021;6:e00977-20. [PMID: 33536323 DOI: 10.1128/mSphere.00977-20] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. Background review for the '2020 European guideline for the diagnosis and treatment of gonorrhoea in adults'. Int J STD AIDS 2021;32:108-26. [PMID: 33323071 DOI: 10.1177/0956462420948739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
17 Jiao H, Yang H, Zheng W, Zhang Q, Zhao D, Li G. Enhancement of immune responses by co-administration of bacterial ghosts-mediated Neisseria gonorrhoeae DNA vaccines. J Appl Microbiol 2021;130:1770-7. [PMID: 32770820 DOI: 10.1111/jam.14815] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Chemaitelly H, Majed A, Abu-Hijleh F, Blondeel K, Matsaseng TC, Kiarie J, Toskin I, Abu-Raddad LJ. Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression. Sex Transm Infect 2021;97:157-69. [PMID: 32423944 DOI: 10.1136/sextrans-2020-054515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Semchenko EA, Chen X, Thng C, O'sullivan M, Seib KL. Gonorrhoea: past, present and future. Microbiol Aust 2020;41:205. [DOI: 10.1071/ma20055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]